Transforming diabetes management: the adoption of technology as a game changer in diabetes care
Published in General & Internal Medicine
In recent years, we have witnessed a remarkable evolution in the management of diabetes, ushering in a new era of treatment that incorporates advanced technology in the management of disease. The adoption of continuous glucose monitoring (CGM), insulin pumps, smart pens and, especially, AI-powered closed-loop solutions has fundamentally changed the way we approach diabetes care. We are hereby delving into the transformative effects of these innovations on diabetes management.
CGM has revolutionized diabetes management by providing real-time data on blood glucose levels. For individuals with diabetes, this means a significant shift from traditional fingerstick measurements to continuous monitoring. The impact of CGM on both people with diabetes and healthcare professionals cannot be overstated. For healthcare professionals, CGM has offered invaluable insights into patients' glucose trends, facilitating more personalized and effective management plans. This allows them to make data-driven decisions and adjust therapies promptly. Moreover, this helps improving patient adherence to treatment. For individuals living with diabetes, CGM is a game-changer. It not only provides a continuous stream of glucose data but also predictive alarms, alerting users to potential high or low glucose levels before they become critical. This has contributed to better glycemic control, fewer hypoglycemic events, and improved overall quality of life.
Continuous insulin infusion devices (insulin pumps) have been a crucial part of diabetes management for many years, offering precise insulin delivery and reducing the need for multiple daily injections. Today's insulin pumps have evolved to be more user-friendly and feature-rich, providing greater flexibility and control. For healthcare professionals, insulin pumps enable a more individualized approach to insulin therapy. By fine-tuning basal rates and offering different bolus options, patients can better mimic the body's natural insulin production. Healthcare providers can work closely with patients to customize their pump settings, helping them achieve better glycemic control. For people with diabetes, insulin pumps not only enhance insulin delivery but also foster a sense of empowerment. The freedom to manage insulin dosages and infusion rates, especially during meals or exercise, empowers individuals to lead more flexible lives. Reduced daily injections and the option to receive insulin discreetly via the pump also contribute to enhanced quality of life.
Nevertheless, perhaps the most exciting development is the integration of artificial intelligence (AI) into diabetes management. Closed-loop systems, often referred to as the "artificial pancreas", combine CGM and insulin pumps with sophisticated AI algorithms to automatically adjust insulin delivery based on real-time glucose levels. This innovation resulted in a big step towards improved glucose control and reduced risk of severe hypoglycemia. For healthcare professionals, AI-powered closed-loop solutions represent a paradigm shift in diabetes management. These systems continuously analyze glucose data and make real-time adjustments to insulin delivery, significantly reducing the need for an external intervention. They allow healthcare providers to focus on refining the system's parameters and troubleshooting, rather than routine insulin adjustments. For individuals with diabetes, closed-loop systems offer peace of mind. The constant glucose monitoring and automated insulin adjustments can help maintain stable glucose levels, reducing the emotional burden of diabetes management. Additionally, these systems have shown great promise in reducing nocturnal hypoglycemia, improving sleep quality, and enhancing overall health and well-being.
While these innovations have already transformed the treatment of type 1 diabetes, their potential impact on type 2 diabetes is equally relevant. The scenario is also changing in the management of individuals with type 2 diabetes, in whom these technologies offer new avenues for personalized care. Many people with type 2 diabetes are also benefiting from CGM, and in the near future also from more advanced insulin delivery solutions and AI-powered solutions.
As we look ahead, ongoing research and development are expected to bring even more breakthroughs. We anticipate better AI algorithms, interoperability between devices, and further improvements in usability. These innovations will not only improve glycemic control but also contribute to the prevention and management of diabetes-related complications.
In conclusion, the adoption of continuous glucose monitoring, insulin pumps or smart injection systems, and AI-powered closed-loop solutions has already revolutionized the way we treat diabetes, benefiting both healthcare professionals and, more importantly, people living with the condition. These innovations have set the stage for a brighter future in diabetes management, with the potential to impact not only type 1 but also type 2 diabetes. The scale of this transformative change is truly fascinating. Embracing these technologies and staying informed about their progress is not just a step forward but a thrilling journey as we collectively work to improve the lives of those affected by diabetes. We should continue to foster the implementation of these technological solutions in diabetes care, knowing that we are witnessing and actively contributing to the transformation in diabetes care.
Follow the Topic
-
Cardiovascular Diabetology
This journal considers manuscripts on all aspects of the diabetes/cardiovascular interrelationship and the metabolic syndrome; this includes clinical, genetic, experimental, pharmacological, epidemiological and molecular biology research.
Related Collections
With Collections, you can get published faster and increase your visibility.
Vascular Drivers of Cardio-Metabolic Disease: Mechanisms and Clinical Implications
Despite advancements in glycemic control, cardiovascular disease remains the leading cause of morbidity in diabetes. The plateau in clinical outcomes suggests that we may have overlooked a complex, multi-organ communication network—the vasculome. This Collection seeks to move beyond traditional glucocentric frameworks to better understand endothelial biology as a dynamic interface integrating metabolic, immune, neural, and hormonal signals. We focus on the concept of the endothelial interactome, a heterogeneous and spatially diverse regulatory system that contributes to vascular dysfunction, organ-specific complications, and cardiometabolic risk.
The aim of this Collection is to provide a high-impact platform for research that characterizes site-specific endothelial heterogeneity and its interactions with peripheral organ systems in cardiometabolic disease. We particularly encourage studies that identify molecular and cellular “signatures” (e.g., angiokines, inflammatory mediators, and metabolic regulators) that contribute to organ-specific vascular complications. By integrating systems biology approaches with clinical and translational data, we aim to advance understanding of disease mechanisms and identify novel targets for prevention, risk stratification, and precision therapy, including strategies that address persistent vascular dysfunction despite metabolic control.
We welcome original research articles, clinical investigations, observational cohort studies, randomized clinical trials, high-level reviews, and translational perspectives.
Topics of interest include, but are not limited to:
- Neuro-Immune-Vascular Axis: Interactions between autonomic regulation, immune activation, and vascular inflammation in cardiometabolic disease
- Sex as a Biological Variable: Sex-specific mechanisms contributing to vascular complications in diabetes and metabolic disease
- Epigenetic and Immune Memory: Mechanisms of vascular “trained immunity” and potential strategies for reversal or modulation
- Systems Medicine Approaches: Multi-omics, computational modeling, and organ-on-a-chip platforms to study endothelial heterogeneity and inter-organ communication
- Clinical Translation: Biomarkers, imaging approaches, and therapeutic strategies targeting vascular dysfunction and improving cardiovascular outcomes in diabetes and related metabolic disorders
We invite contributions that bridge basic, translational, and clinical research to advance a more integrated understanding of vascular disease in cardiometabolic disorders. Our goal is to translate mechanistic insights into meaningful clinical outcomes that improve prevention, diagnosis, and treatment in metabolic disease.
All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.
Publishing Model: Open Access
Deadline: Jun 09, 2027
Cardiometabolic and Hepatic Interconnections: From Mechanisms to Clinical Implications
Cardiovascular Diabetology features a Collection on "Cardiometabolic and Hepatic Interconnections: From Mechanisms to Clinical Implications". This is a companion Collection with Diabetology & Metabolic Syndrome with the title "MASLD Beyond the Liver: Epidemiology, Pathophysiology, Diagnosis, and Therapeutic Implications in Multisystem Disorders".
Cardiometabolic and liver diseases are no longer viewed as isolated entities. Growing evidence shows that hepatic and cardiovascular dysfunctions are tightly interconnected through shared metabolic, inflammatory, hemodynamic, and hormonal pathways. This crosstalk shapes disease trajectories and opens opportunities for integrated diagnostics and therapies.
Key interconnections include:
- Insulin resistance. The liver is pivotal for glucose and lipid homeostasis. Hepatic insulin resistance drives excess glucose production and dyslipidemia, contributing to the cardiovascular–kidney–metabolic (CKM) syndrome.
- Metabolic dysfunction–associated steatotic liver disease (MASLD). Highly prevalent in obesity and metabolic syndrome, and especially common in type 2 diabetes (T2D), which bears the highest MASLD burden. Progression to steatohepatitis or fibrosis markedly increases atherosclerotic risk.
- Liver-derived factors. Hepatokines (e.g., FGF21) and extracellular vesicles influence cardiac tissue, vascular tone, and systemic metabolism, potentially amplifying inflammation, oxidative stress, and lipotoxicity across organs.
- Systemic inflammation and lipotoxicity. Visceral adipose tissue and the liver release inflammatory cytokines and triglyceride-rich lipids, promoting endothelial dysfunction and perpetuating metabolic disturbances.
- Dyslipidemia. Elevated triglycerides and LDL, with reduced HDL, accelerate atherogenesis and cardiovascular risk.
- Hemodynamic and metabolic stress. Heart failure can cause hepatic congestion and hypoperfusion, while advanced liver disease can precipitate cirrhotic cardiomyopathy and arrhythmias, even in the absence of prior heart failure.
In summary, hepatic and cardiometabolic systems are functionally and pathologically intertwined: liver dysfunction worsens cardiovascular and metabolic health, and cardiometabolic disturbances accelerate hepatic pathology.
This Collection welcomes original research articles, reviews, and meta-analyses focused on this reciprocal relationship. Given the high prevalence of MASLD in T2D, we especially encourage submissions at the T2D–MASLD–cardiovascular interface. Addressing hepatic and cardiometabolic health in parallel is essential for effective risk reduction and patient care.
This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.
All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.
Publishing Model: Open Access
Deadline: Oct 31, 2026
